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Abstract
In studies based on electronic health records (EHR), the frequency of covariate moni-
toring can vary by covariate type, across patients, and over time. This can lead to major
challenges: first, the difference in monitoring protocols may invalidate the extrapolation
of study results obtained in one population to the other, and second, monitoring can act
as a time-varying confounder of the causal effect of a time-varying treatment on the out-
comes of interest. This paper demonstrates how to account for non-systematic covariate
monitoring when evaluating dynamic treatment interventions, and how to evaluate joint
dynamic treatment-censoring and static monitoring interventions, in a real world, EHR-
based, comparative effectiveness research (CER) study of patients with type II diabetes
mellitus. First, we show that the effects of dynamic treatment-censoring regimes can be
identified by including indicators of monitoring events in the adjustment set. Second, we
demonstrate the poor performance of the standard inverse probability weighting (IPW)
estimator of the effects of joint treatment-censoring-monitoring interventions, due to
a large decrease in data support resulting in a large increase in standard errors and
concerns over finite-sample bias from near-violations of the positivity assumption for
the monitoring process. Finally, we detail an alternate IPW estimator of the effects of
these interventions using the No Direct Effect assumption. We demonstrate that this
estimator can result in improved efficiency but at the cost of increased bias concerns
over structural near-violations of the positivity assumption for the treatment process.
To conclude, this paper develops and illustrates new tools that researchers can exploit
to appropriately account for non-systematic covariate monitoring in CER, and to ask
new causal questions about the joint effects of treatment and monitoring interventions.
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1 Introduction
1.1 Dynamic treatment regimes and non-systematic covariate mon-
itoring in longitudinal studies
In the management of chronic conditions such as diabetes, adaptive treatment strategies
(a.k.a. dynamic treatment regimes) might often lead to better outcomes than non-adaptive
treatment strategies (a.k.a. static treatment regimes).1 In addition, adaptive treatment
strategies better reflect real-world decision making because they allow for the update of
treatment decisions over time as a function (hereinafter, referred to as a decision rule) of
the changing circumstances (e.g. prognosis) of the individual patient. Dynamic treatment
regimes can be evaluated using randomised experiments (SMART trials, see e.g. (2)) and
increasingly in comparative effectiveness research, using observational studies.3,4, 5
Regardless of the study design, evaluating adaptive treatment strategies requires data col-
lection on covariates that enter the decision rules of interest. For example, for the treatment
of HIV, adaptive treatment strategies such as "start treatment when CD4 count first drops
below 350" require that patient’s CD4 count be measured over time. The pattern and fre-
quency of covariate measurements vary across study designs. In randomised trials, covariates
are typically measured at regular intervals but the lengths of intervals between monitoring
events can also vary over time and by covariate type within the same experiment.6 In widely
employed observational study designs (e.g. retrospective cohort studies based on electronic
health records7), monitoring is typically a joint decision of the patient and the health care
providers, and is thus not expected to be synchronized between patients as would be the case
in observational studies (e.g., some prospective cohort studies) in which investigators exert
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more direct control on the data collection protocols.
Thus, the frequency of covariate measurements can greatly vary by covariate type, across
patients, and over time in observational data derived from EHR-based cohort studies. For
example, in two studies of antiretroviral treatments, (8) collect covariate information every
7 days, while (9) use a 180-day intervals of measurement. This monitoring variability can
lead to challenges but also new opportunities for research that is based on the evaluation of
adaptive treatment strategies for the following three reasons.
First, when aiming to establish the optimal dynamic treatment regime, optimality will
likely depend on the frequency of monitoring.9 For example, in a diabetes population where
hemoglobin A1c (A1c) is monitored every year, the optimal A1c threshold for treatment in-
tensification (e.g., addition of a drug to protect against microvascular complications) might
differ from that in a population where A1C is monitored every 3 months. One might expect
that, in the first population, a more aggressive treatment strategy (i.e., treatment intensifi-
cation at a lower A1c level) is necessary to avoid the adverse health outcomes from delays in
treatment intensification that would be caused by infrequent clinical monitoring if patients
were treated according to the optimal A1c threshold for treatment intensification in the sec-
ond population.9 Hence, the difference in monitoring protocols between two populations may
invalidate the extrapolation of study results obtained in one population to the other.
Second, monitoring in itself is a health intervention with non-negligible costs to health-
care systems that can also burden patients financially or otherwise (e.g., monitoring can
cause discomfort or adverse events in case of invasive procedures such as biopsies). Hence
establishing the optimal monitoring intervention may be of interest in its own right. As illus-
trated in the previous paragraph, evaluating joint interventions that intervene on both the
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monitoring regime (for example, "monitor every 6 months") and on the treatment regime is
also of particular interest to enhance the generalizability of study findings when evaluating
adaptive treatment strategies.
Third, monitoring can act as a time-varying confounder of the causal effect of a time-
varying treatment on the outcomes of interest. Patients with frequent monitoring events may
be very different from patients who rarely interact with the health care system, with respect
to (possibly unobserved) characteristics such as disease severity or health related behaviour,
and these characteristics may also impact patient outcomes. Hence, in observational studies
and in particular those based on retrospective cohort studies, accurate estimation of the
causal effect of dynamic treatment regimes may often require adjustment for the occurrence
of monitoring events.
While statistical methods for estimating the causal effects of dynamic treatment regimes
are well developed,10,3, 11,12,9, 13,14 there is little practical guidance on how to handle the chal-
lenges of non-systematic monitoring and how to exploit monitoring variability to evaluate
its impact on health outcomes and improve the generalizability of study results. (9) develop
estimators for the joint optimal treatment-monitoring strategies. One particular issue high-
lighted by (9) is the requirement for a positivity assumption about the monitoring process
that generated the study data: more specifically, conditional on a subject’s past observed
variables, it is required that there is a positive probability for that subject to follow various
monitoring regimes of differing monitoring intervals (e.g., monitoring every 3 months versus
every 3 years). This requirement, in real world settings, may often be implausible. The
estimator they propose weakens the positivity assumption requirement for monitoring by in-
troducing the "no direct effect" (NDE) assumption that requires that the monitoring decision
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can only impact the outcome through subsequent treatment decisions, for example excluding
the possibility of monitoring affecting diet and physical activity which, in turn, would impact
health outcomes. (15) build on these results within the nonparametric structural equation
modeling framework by deriving new identifiability results that facilitate the construction of
estimators of effects defined by general joint treatment and monitoring interventions, using
the same NDE assumption.
Beyond (6), who apply some of the methods proposed by (9) to estimate the joint effect
of CD4 monitoring and antiretroviral therapy initiation strategies in HIV infected adults,
there are, to our knowledge, no published studies that explore the challenges posed by non-
systematic monitoring in a real world case study. As observational studies make increasing
use of routinely collected longitudinal data sources which were not originally intended for
research purposes (e.g., electronic health records data), the development of methods and
practical guidelines for handling non-systematic monitoring in the evaluation of longitudinal
treatment regimes is necessary. This paper demonstrates how to tackle the challenges and
opportunities just described in a real world case study based on electronic health records
(EHR) data.
1.2 A case study to illustrate and evaluate the practical perfor-
mance of IPW estimation to control for non-systematic covari-
ate monitoring: the TI study
We build on a retrospective cohort study designed to evaluate progressively more aggressive
glucose-lowering strategies on clinical outcomes of adults with type II diabetes mellitus.16,17
The study is based on a large, longitudinal, EHR data set of 51,179 patients from the Health
Maintenance Organization (HMO) Research Network.18 The dynamic treatment interven-
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tions under consideration require that a patient initiates treatment intensification (TI) at
the first time her A1c level reaches or drifts above x% and that the patient remains on the
intensified therapy thereafter, with x = 7, 7.5, 8, or 8.5. To appropriately account for time-
dependent confounding and informative censoring, dynamic marginal structural modelling
was employed, using inverse probability weighting (IPW) and targeted minimum loss based
estimation.19,20,21 Findings from this observational study demonstrated the benefit of tight
glycemic control with respect to the development or progression of albuminuria.
We build on the various methodological approaches applied to date in this study by now
addressing the problem of non-systematic monitoring when estimating the comparative effec-
tiveness of the four treatment intensification strategies described above. We first revisit how
prior IPW estimation were implemented to discuss an assumption about monitoring events
that has, to our knowledge, not been highlighted in the literature despite its common but
implicit adoption in prior work on the evaluation of dynamic treatment regimes. Here, we
relax this assumption and describe practical implications for constructing consistent IPW
estimators of the effects of dynamic treatment regimes. Second, we describe the standard
IPW estimation of the effects of joint treatment-censoring-monitoring interventions (for ex-
ample, monitor A1c every 6 months, and intensify treatment when A1c first exceeds 7.5%).
Finally, we detail an alternate approach that was proposed to handle the practical limitations
expected to arise when implementing this standard IPW estimator. More specifically, using
identification results from (15), we describe an alternate IPW estimator of the effects of joint
monitoring-treatment interventions using the no direct effect assumption. In each section, we
illustrate and evaluate the practical performance of the analysis described using data from
the aforementioned diabetes study.
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For each analysis, we describe the causal estimands, their identifiability assumptions,
a distinct IPW estimator, and its implementation for evaluating the causal estimands. We
present results in terms of both estimated counterfactual survival curves and estimated coun-
terfactual cumulative risk differences. Throughout we use IPW estimators of the counter-
factual hazards whose estimates are then mapped into survival probability estimates. All
analyses were implemented using the stremr R package.22
1.3 Observed data notation
While EHR data are captured in continuous time (i.e. information such as medication dis-
pensed or results from lab exams are stamped with event dates and times), it is common
practice to first coarsen granular EHR data by mapping them into the organized structure
described below using a discrete time scale chosen by the analyst. This data structure is
motivated by the widely used framework developed in the literature for effect estimation
with complex observational longitudinal data such as the evaluation of dynamic treatment
effects.23,11,9 All analyses in this report are based on an analytic dataset constructed with
the MSMstructure SAS macro24 to coarsen daily EHR data using the 90-day time unit. We
now describe the random variables whose realizations on each of 51,179 patients make up the
analytic data set.
For each patient in the cohort, measurements on treatment, covariate, censoring and
outcome information are updated every 90 days starting at study entry and until the end of
follow-up. Follow-up time (denoted by t) is thus expressed in 90-day units. By convention,
the first 90 days of follow-up is denoted by t = 0. The end of follow-up is the earliest of
the time to the failure event (i.e., albuminaria development or progression), or the time to
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a censoring event (i.e., death, disenrollment from the health plan, or administrative end of
study). The latest possible follow-up time (expressed in 90-day units) is denoted by K+1 =
36, corresponding to about 9 years. The binary outcome variable Y (t) represents whether
the failure event occurred at the previous time point t− 1, and Y (0) = 0 by convention. The
vector A(t) = (A1(t), A2(t)) denotes the exposure status at time t and is composed of two
binary variables A1(t) and A2(t) that indicate whether the patient experienced an intensified
therapy and a censoring event at time t, respectively.
The vector of covariates Z(t) represents various patient attributes measured before A(t)
(e.g., comorbidity diagnoses or vital signs). The covariate I(t) denotes the patient attribute
measured before A(t) that is involved in the definition of the dynamic treatment regimes of
interest, i.e., the A1c level. This is also the covariate whose monitoring frequency plays a
central role in the evaluation of the dynamic treatment regimes and for which the evaluation
of monitoring interventions also becomes of interest. Note that I(t) is not necessarily mon-
itored at every t > 0 for all patients in this study. The binary variable N(t) represents the
monitoring decision at time t and indicates whether a measurement for I(t+1) will be taken.
By convention, when A1c is not monitored at time t, I(t) is defined as I(j) where j < t
is the latest time point when A1c was monitored. By study design, in the first period A1c
is always monitored. We jointly denote the outcome and covariates at time t by the vector
L(t) ≡ (Y (t), Z(t), I(t)) which, by definition, consists of measurements obtained before the
exposure A(t).
To sum-up, the observed data are realizations of n copies Oi of the following temporally
9
ordered sequence of random variables:
O = (L(0), A(0), N(0), ...., L(K), A(K), N(K), L(K + 1))
where, by convention, all variables become degenerate after a failure or censoring event occurs.
Following typical practice, the analyses in this report assume that the random variables Oi
are independent and identically distributed. To simplify notations below, we use the overbar
to denote the history of a variable. For example, Z¯(t) denotes the history of covariate Z from
baseline to time t, i.e., Z¯(t) = (Z(0), . . . , Z(t)). By convention, L(t), A(t), and N(t) are nil
when t < 0.
1.4 Causal Model
We assume a nonparametric structural equation model (NPSEM)25,26 linking the observed
data distribution to a vector of random disturbances and a fixed vector of functions, described
in detail in (15). In this NPSEM, the observed level of the A1c, I(t), is linked to a latent
variable I0(t) that represents the patient’s underlying A1c level at time t. More specifically,
if a decision to measure I0(t) was made during follow-up (i.e., N(t − 1) = 1), we then
observe I(t) to be I0(t), and otherwise the value of I0(t) is missing from the observed data
O. Because A1c is always monitored in the first period, we have I(0) = I0(0) for all patients.
This NPSEM also defines all counterfactual outcomes27 whose distributions define the various
causal estimands of interest in this report.
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2 Evaluation of dynamic treatment regimes: a review to
highlight special considerations for studies with non-
systematic clinical monitoring
2.1 Causal estimands
We consider four distinct longitudinal treatment-censoring interventions which each sets the
random variable A(t) = (A1(t), A2(t)) to a possible realisation a(t) = (a1(t), a2(t)) for each
time period, t = 0, ..., t0 where t0 < K is the time point chosen by the analyst when outcomes
are compared between intervention groups. Specifically, we focus on dynamic treatment
regimes where the values of a1(t) are not pre-defined (such as "always treat" or "never treat")
but adapted to time-varying realizations of patient characteristics based on the following
decision rules applied through failure occurrence: "intensify diabetes treatment the first time
A1c reaches or drifts above x%, and keep patient on the intensified therapy thereafter" with
x=7;7.5;8;8.5. In addition, the four interventions of interest also require that patients do
not experience a censoring event, i.e., a¯2(t0) = 0, to ensure that the outcome at t0 is always
observed.
Formally, each of the four interventions above requires to set the treatment value to
a1(t) = 1 (i.e., initiate an intensified treatment) for a patient who has not failed yet (i.e.,
Y (t) = 0) and who has not received intensified treatment before, (A¯1(t − 1) = 0) but for
whom a new measurement of the A1C has been taken (N(t − 1) = 1) and its level has
reached or exceeded a certain threshold I(t) ≥ x. Otherwise, for a patient who has not
yet failed, and who has also not received an intensified treatment before and for whom a
new A1c measurement has been taken (N(t − 1) = 1) but its level I(t) has not reached or
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exceeded the threshold, the intervention requires that this patient not initiate an intensified
treatment (set a1 to 0). For a patient who has not failed yet and who, either, did not
undergo a new A1c test (N(t − 1) = 0), or had already initiated an intensified treatment
previously (A¯(t − 1) = 1), then the intervention requires that treatment be not changed,
i.e a1(t) = a1(t − 1), corresponding to "no treatment initiation" if the patient was not on
intensified treatment before, and to "continuation of the intensified treatment" if the patient
had already initiated it. Each intervention also requires to set the censoring variable a2(t) to
value 0 in any case. Once, the patient has failed (i.e., Y (t) = 1), the intervention stops or,
equivalently, the interventions can be defined as requiring that the patient’s exposure a(t)
remains unchanged after failure (i.e., a1(t) = a1(t− 1) and a2(t) = 0).
We denote the decision rules that define the four interventions described above with four
vectors of mappings dx = (dx(0), . . . , dx(K)) where dx(t) : (A(t− 1), N(t− 1), Y (t), I(t)) 7→
(a1(t), a2(t)) for t = 0, ..., K and x ∈ X = {7, 7.5, 8, 8.5}. To simplify notation below, the
exposure regime through time t defined by applying the sequence of decision rules dx with
a patient’s observed data O is denoted by dx(V¯ (t)) = (dx(0)(V (0)), . . . , dx(t)(V (t))), where
the vector V(t) is defined as V (t) = (A(t−1), N(t−1), Y (t), I(t)). For a given A1c threshold
x, we note that this exposure regime is not necessarily equal to the intervention of interest
because, for example, we might have A(0) ̸= dx(V (0)).
In Section 2, we are interested in the counterfactual outcomes defined by the joint dynamic
treatment-censoring intervention described above. Formally, these outcomes are defined by
the NPSEM introduced in Section 1.4 and denoted by Ydx(t + 1). Contrasts of their distri-
butions define the first set of causal parameters of interest in this report. More specifically,
we first aim to estimate the difference in the counterfactual cumulative risk of failure at
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time t0 between any two distinct regimes dx1 and dx2 : ψdx1 ,dx2 (t0 + 1) = P (Ydx1 (t0 + 1) =
1)− P (Ydx2 (t0 + 1) = 1).
2.2 Identifying assumptions
Identifiability of the above parameters with observational data relies on the no unmeasured
confounding, and positivity assumptions.11,9
In the setting of longitudinal treatment interventions, the no unmeasured confounding
assumption is also referred to as the sequential randomization assumption (SRA) which states
that, conditional on the observed treatment and confounder history, each potential outcome
of interest is independent of exposure status in each preceding time period. In settings
where monitoring is performed in each period (i.e., when N¯(K − 1) = 1), the sequential
randomization assumption is stated as follows:
Ydx(t0 + 1) ⊥ A(t)|L¯(t), A¯(t− 1), (1)
for t = 0, ..., t0, and x ∈ X . This assumption is not testable in practice but its upholding
requires that a sufficiently rich set of covariates are measured. Substantive subject-matter
knowledge encoded in a causal diagrams may be used to inform the selection of relevant
covariates (e.g., using the sequential back-door criterion28), but the adequacy of the selection
then rests on the correct specification of the causal Directed Acyclic Graph (DAG) and in
particular on the ability to assume that all common causes of any two nodes in the DAG
are known.25,28,29,30,31,32 For instance, the causal DAG at the top of Figure 1 represents
commonly assumed causal relationships between observed treatment, covariates, and out-
comes that support the upholding of the SRA in studies where covariates are monitored
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systematically at each time point (i.e., I(t) = I0(t)). This DAG is the analog of the one
presented in figure 1b of (33) but adapted to cohort studies with a time-to-event outcome.
For simplicity, it is assumed that no covariate other than the A1c measurements and out-
comes are collected (i.e., Z(t) is nil), that follow-up spans only two time points (i.e., K = 1),
and that right-censoring does not occur (i.e., A¯2(K) = 0 and the degenerate censoring nodes
are thus omitted from the DAG just like the degenerate monitoring nodes N¯(K) = 1). We
note however that the arguments below hold in the more complex and realistic study sce-
narios with additional covariate nodes Z(t), the occurrence of censoring events A2(t), and
longer follow-up. In this DAG, each observed variable of the temporally ordered sequence
O is assumed to possibly affect all subsequent observed variables. In particular, we note
that the first outcome measurement Y (1), has an effect on the second outcome measurement
Y (2), the second covariate meausurement I(1), and the second treatment measurement A1(1)
which reflects the convention that all variables become degenerate after failure. In addition
to the observed variables, the DAG also includes two potentially unobserved time-varying
covariates U1 and U2 (e.g., health-seeking behavior such as diet and physical activity in the
TI study) that, as indicated by the dashed arrows, are risk factors for the outcomes Y (t)
and determinants of the covariates I(t). The covariate U2 may also be impacted by the prior
observed covariate I(0) and treatment A1(0). Because all backdoor paths from the treatment
nodes A1(0) and A1(1) to the outcomes Y (1) and Y (2) are blocked by observed variables,
the SRA holds. This DAG demonstrates that the SRA (1) will hold even in the presence of
unmeasured risk factors for the outcome as long as the effects of these factors on treatment
decisions are entirely mediated by covariates that are included in the observed data.
The study scenario just described can be extended to studies with non-systematic mon-
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itoring of covariates as shown by the DAG at the bottom of Figure 1. This second DAG is
obtained by replacing the node I(1) = I0(1) in the first DAG with three new nodes: the
indicator of A1c monitoring, N(0), the latent A1c level I0(1), and the observed A1c level,
I(1). All parents of the node I(1) = I0(1) in the first DAG remain parents of the node I0(1)
in the second DAG. Of the two children A1(1) and Y (2) of the node I(1) = I0(1) in the first
DAG, only the node Y (2) remains a child of I0(1) in the second DAG.
The absence of an arrow from I0(1) to A1(1) encodes the assumption that the covariate
I0(1) can only impact treatment decisions if it is observed (e.g., a clinician’s decision to
prescribe a new treatment cannot be influenced by the patient’s A1c level if this level was
not known to the clinician). Following the same rationale, both N(0) and I(1) become
parents of the treatment node A1(1). We recall that the observed A1c measurement I(1)
is defined as I0(1) if both N(0) = 1 and Y (1) = 0. Otherwise, the covariate is defined by
convention as the last observed value carried forward (LOVCF), i.e., I(0). Therefore, the
only parents of I(1) in the second DAG are I(0), N(0), Y (1), and I0(1). The node N(0) is
assumed to possibly impact directly both the latent covariate I0(1) and the outcomes Y (1)
and Y (2).
In the second DAG, the following SRA holds since all backdoor paths between treat-
ment nodes and outcomes are blocked by past observed outcomes, covariates, treatment, and
monitoring nodes:
Ydx(t0 + 1) ⊥ A(t)|L¯(t), A¯(t− 1), N¯(t− 1) (2)
In the second DAG, several backdoor paths from the treatment node A1(1) to the outcome
Y (2) are not blocked by the observed covariates I(0), I(1), treatment A1(0), and the outcome
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Y (1): e.g., A1(1)–N(0)–Y (2), A1(1)–N(0)–U1–Y (2), and A1(0)–N(0)–I0(1)–Y (2). The SRA
as formulated by expression (1) may thus lead to biased estimation of the causal estimands
ψdx1 ,dx2 in studies with non-systematic covariate monitoring if the monitoring variables N(t)
are not controlled for when applying methods based on the G-formula.34 For example, bias
could be expected from an IPW estimator constructed from propensity scores estimated
with models that ignored the monitoring nodes. We note that the same concern also applies
to causal estimands defined by static interventions on time-varying exposures. While the
use of LOVCF to define covariate processes such as I¯(t) in studies with non-systematic
covariate monitoring has become routine practice in the literature,4,16,5, 6 it is not clear that
adjustment for the associated monitoring process N¯(t) has become common practice. The
use of LOVCF without control for the process N¯(t) in studies with non-systematic covariate
monitoring35,36,37 can be viewed as an attempt to impute missing data on time-varying
covariates such as I0(t) (i.e., when N(t− 1) = 0) in order to emulate the observational study
design represented by the first DAG in which covariates are collected at each time point (i.e.,
as if N¯(t) = 1). The second DAG in Figure 1 demonstrates that unmeasured latent covariates
such as I0(t) do not necessarily lead to biased effect estimation if the monitoring process N¯(t)
is adjusted for in the analysis and if it can be assumed that the effect of the latent variables on
treatment decisions is entirely mediated by the observed covariate values I(t) (an exclusion
restriction assumption). Imputation of I0(t) is then an unnecessary goal and, in fact, the
second DAG shows that even if the imputation process is successful, residual confounding
might be expected if the monitoring process N¯(t) is not controlled for (e.g., when constructing
propensity scores for IPW estimation) because, for example, two of the backdoor paths from
A1(1) to Y (2) through N(0) (via U1 and U2) would then remain open. Instead of viewing
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unmeasured values for covariates I0(t) as missing data, the second DAG of Figure 1 thus
argues for an alternate approach in which the monitoring nodes N¯(t) are explicitly included
in the observed data structure O (as done in Section 1.3 or by including them in the vector
of covariates L(t)). With this data structure, the SRA as originally formulated in (38) is
equivalently expressed as (2) and its upholding can be supported by the exclusion restriction
assumption above. We argue here that this assumption is often realistic for many covariates
such as laboratory measurements in EHR-based studies and that controlling for monitoring
nodes N¯(t) can then not only avoid the difficult goal of correctly imputing missing values
for latent variables such as I0(t) but can also potentially prevent residual confounding from
unblocked paths from A1(1) to outcomes Y (2) through N(0) in Figure 1.
In both studies with systematic and non-systematic covariate monitoring, identifiability
of the causal estimands ψdx1 ,dx2 also hinges on upholding of a positivity assumption. It re-
quires that for each regime dx, in each period through t0, patients have a positive probability
of following that regime, conditional on having followed it up to that time point, not having
failed yet, and any combination of their observed covariate, outcome, monitoring, and expo-
sure history. We state the positivity assumption for studies in which covariate monitoring is
not systematic:
P
(
A(t) = dx(t)(V (t))
∣∣∣ L¯(t), Y¯ (t) = 0, A¯(t− 1) = dx(V¯ (t− 1)), N¯(t− 1)) > 0, (3)
for t = 0, . . . , t0.
17
Figure 1: Examples of two Directed Acyclic Graphs (DAGs). The top DAG represents a
commonly assumed scenario in cohort studies with time-varying covariates monitored at
each time point (33, Figure 1b)
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2.3 A hazard-based, bounded, IPW estimator
To estimate the causal risk difference, ψdx1 ,dx2 (t0 + 1) under the SRA (2), we first separately
estimate the two counterfactual cumulative risks P (Ydx(t0 + 1) = 1) with x = x1, x2 by IPW
estimation. Second, we take the difference between the resulting estimates and base inference
on the delta method.
More specifically, we evaluate each counterfactual risk using bounded IPW estimators
of the discrete-time counterfactual hazards of failure. We selected this hazard-based IPW
estimator because it is expected (as demonstrated in prior practical work20) to be more
efficient than alternate, more direct IPW estimators of the cumulative risks.
The bounded IPW estimator of each counterfactual hazard is denoted by Pn(Ydx(t+1) =
1|Ydx(t) = 0) and defined as a convex, linear combination of the outcomes at time t + 1
from all patients who did not experience the event before or at time t, and who followed the
intervention of interest through time t:
n∑
i=1
hi(t)∑n
i=1 hi(t)
Yi(t+ 1), (4)
where hi(t) is the inverse probability weight for individual i defined by the function
h(t) = I(Y (t) = 0, A¯(t) = dx(V¯ (t)))
∏t
j=0 P
′
n(A(j) = dx(j)(V¯ (j))|A¯(j − 1) = dx(V¯ (j − 1)))∏t
j=0 Pn(A(j)|L¯(j), A¯(j − 1), N¯(j − 1))
,
(5)
where I(·) denotes the indicator that event · occurs, Pn(A(j)|L¯(j), A¯(j−1), N¯(j−1)) denotes
an estimate of the conditional probability of the observed exposure at time j, given the
past covariates, exposures, and monitoring decisions (i.e., the estimated propensity score for
exposure when A(j) = 1), and P ′n(A(j) = dx(j)(V¯ (j))|A¯(j−1) = dx(V¯ (j−1))) is a stabilizing
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factor, denoting the estimated probability of a patient following the regime dx of interest at
time j given that she followed the dynamic regime through time j − 1.
As noted elsewhere,20 this estimator is equivalent to a stabilized IPW estimator of the
coefficients of a saturated logistic dynamic marginal structural model (MSM) for the coun-
terfactual hazards under the dynamic interventions dx with x ∈ X when these hazards are
strictly between 0 and 1.11,9 Such a dynamic MSM can be fitted with a standard weighted lo-
gistic regression using an expanded dataset4 where each person-time observation is replicated
for each dynamic regime a person follows at each time point. The weights to be used are the
estimated inverse probability (IP) weights hi(t) defined above. We note that, when the MSM
for the hazards is saturated, the use of stabilized IP weights hi(t) or their unstabilized version
(i.e., (5) in which the probabilities P ′n are replaced by 1) lead to the same IPW estimator
(because these probabilities in the numerator and denominator of (4) cancel out), i.e., weight
stabilization does not confer the gains in efficiency that originally motivated the stabilization
of IP weights.39 The estimated coefficients from the MSM fit are then transformed to obtain
the estimate of the hazards, which are then mapped into an estimate of the counterfactual
cumulative risk difference the following way:
ψ
dx1 ,dx2
n =
t0∏
t=0
(
1−Pn(Ydx2 (t+1) = 1|Ydx2 (t) = 0)
)
−
t0∏
t=0
(
1−Pn(Ydx1 (t+1) = 1|Ydx1 (t) = 0)
)
,
where ψdx1 ,dx2n denotes the hazard-based IPW estimator of the causal estimand ψdx1 ,dx2 . For
conciseness, we do not detail here a conservative estimator of its variance which is given in
the Appendix of (20).
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2.4 Implementation
In prior work,20 the causal estimands ψdx1 ,dx2 were evaluated with the IPW estimator just
described but its implementation implicitly relied on the SRA (1) instead of SRA (2). More
specifically, the propensity scores that define the denominator of the weights (5) were esti-
mated using models that ignored the monitoring variables N¯(j − 1) and only considered the
covariates L¯(j) and exposures A¯(j − 1).
Motivated by the rationale on the upholding of the SRA in studies with non-systematic
covariate monitoring outlined in Section 2.2, we revisit here the implementation of IPW
estimation in the TI study to evaluate the practical impact of including versus excluding
summary measures of the monitoring variables N¯(j−1) as new terms in the propensity score
models that define the inverse probability weights (5).
In order to estimate the probability of the observed exposure given the observed past
P (A(j)|L¯(j), A¯(j− 1), N¯(j− 1)) referred to as the exposure assignment mechanism, we esti-
mate separate propensity scores for the treatment and the censoring variables using various
logistic models described in detail in prior work
We calculated the past frequency of A1c monitoring at each time point by dividing the
number of prior periods in which A1C was monitored by the number of periods up to that
time point, and we then created a categorical variable resulting in five categories approx-
imately corresponding to the quintiles of the variable over all patients and time points:
[0, 0.4),[0.4, 0.5), [0.5, 0.7), [0.7, 1) and [1], the last category describing those always moni-
tored.
The categorical variable indicating whether the latest A1C measurement was monitored
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at the current period or carried forward from a previous period takes the value of 0 if the
measurement was monitored at the current period (i.e., N(j − 1) = 1), 1 if it was monitored
at the previous period (i.e., N(j − 2) = 1, N(j − 1) = 0), 2 if it was monitored two periods
earlier (i.e., N(j − 3) = 1, N(j − 2) = N(j − 1) = 0), and so on, setting any levels higher
than 4 to the value of 4. These categorical variables are then interacted with the latest
measurement of A1C.
For covariates Z(j) (e.g. LDL, blood pressure) that were not systematically monitored
at each time point j, we followed a similar approach as the one used for I(j), i.e., we used
LOVCF to define the covariate when it was not monitored, and included the indicators of
last value being carried forward in the vector of covariates L(j) that define the main terms
included in the logistic models for the propensity scores.
The estimates of the probabilities P ′n that define the numerators of the IP weights (5) were
derived non-parametrically using proportions of observed events. The resulting estimated
stabilized IP weights were truncated39 at the value 40.
2.5 Results
Figure 2 shows the estimated counterfactual survival curves over the first 2 years of follow-
up before and after covariate adjustment with IPW for the four dynamic regimes studied.
Figure 3 shows the adjusted point and interval estimates of the corresponding counterfactual
cumulative risk differences. These results replicate the findings from prior analyses: Whereas
unadjusted estimates of the cumulative risks provide little evidence of a protective effect of
increasingly more aggressive treatment intensification strategies, adjusted estimates provide
strong evidence that the risk of albuminuria development or progression almost always de-
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creases with the progressive decrease of the A1c threshold at which treatment intensification
is initiated.
Tables 1 and 2 show the distribution of the stabilized and untruncated inverse probability
weights among all person-time-regime observations who contribute an outcome to the effect
estimates (i.e., an outcome that is assigned a nonzero IP weight) during the first 8 quarters
of follow-up when the weights are estimated with logistic models that, respectively, ignore
and include terms for the A1c monitoring variable N(j − 1) and their analogs for the other
covariates Z(j). We note a decrease in the number of large weights when derived with adjust-
ment for monitoring (e.g., only 13 out of 651,250 IP weights are larger than the truncation
level 40 compared to 28 IP weights>40 in the analysis without adjustment for monitoring).
This change can be surprising given that, in our experience, the frequency of large weights
often tend to increase as the number of covariates considered increases. The decrease in the
frequency of large weights has little impact on the estimates of the survival curves (Figure 2)
but leads, as expected,39 to slightly more precise effect estimates as shown (Figure 3) by the
estimated confidence intervals of the counterfactual risk differences over the first 8 periods
of follow-up (2 years).
While results from these analyses do not demonstrate the potential for improved con-
founding adjustment when monitoring variables are included in the adjustment set, they
do however illustrate that the inclusion of monitoring variables in the adjustment set does
not impede appropriate confounding adjustment and that it can also improve estimation
efficiency.
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Figure 2: Crude (top right) and IPW estimates of the four counterfactual survival curves
without (bottom left) and with (bottom right) adjustment for covariate monitoring in the
propensity scores. The top left histogram displays the count of patients following each of
the four dynamic treatment interventions over time.
24
l l l
l l l l
l
l
l l
l l
l l
l
l
l
l
l
l l
l
l
l
l l
l
l
l
l
l
l
l
l
l l l
l
l
l l l
l
l l
l l
d8.0 v d7.5 d8.0 v d7.0 d7.5 v d7.0
d8.5 v d8.0 d8.5 v d7.5 d8.5 v d7.0
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
−0.10
−0.05
0.00
0.05
0.10
−0.10
−0.05
0.00
0.05
0.10
Time
R
is
k 
D
iff
e
re
n
ce
l l l
l l l l
l
l l
l l
l
l l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l l l
l
l
l l l
l
l l
l l
d8.0 v d7.5 d8.0 v d7.0 d7.5 v d7.0
d8.5 v d8.0 d8.5 v d7.5 d8.5 v d7.0
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
−0.10
−0.05
0.00
0.05
0.10
−0.10
−0.05
0.00
0.05
0.10
Time
R
is
k 
D
iff
e
re
n
ce
Figure 3: IPW estimates of counterfactual risk differences without (top) and with (bottom)
adjustment for covariate monitoring in the propensity scores. The shaded areas represent
the 95% confidence intervals.
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Table 1: Distribution of stabilized inverse probability weights derived from propensity
scores estimated based on logistic models without adjustment for covariate monitoring.
Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 95631 14.68 95631 14.68
[0.5, 1[ 496502 76.24 592133 90.92
[1, 10[ 53549 8.22 645682 99.15
[10, 20[ 4932 0.76 650614 99.90
[20, 30[ 540 0.08 651154 99.99
[30, 40[ 68 0.01 651222 100.00
[40, 50[ 21 0.00 651243 100.00
[50, 100[ 7 0.00 651250 100.00
[100, 150[ 0 0.00 651250 100.00
≥ 150 0 0.00 651250 100.00
Table 2: Distribution of stabilized inverse probability weights derived from propensity
scores estimated based on logistic models with adjustment for covariate monitoring.
Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 106538 16.36 106538 16.36
[0.5, 1[ 481807 73.98 588345 90.34
[1, 10[ 59725 9.17 648070 99.51
[10, 20[ 2816 0.43 650886 99.94
[20, 30[ 294 0.05 651180 99.99
[30, 40[ 57 0.01 651237 100.00
[40, 50[ 8 0.00 651245 100.00
[50, 100[ 5 0.00 651250 100.00
[100, 150[ 0 0.00 651250 100.00
≥ 150 0 0.00 651250 100.00
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3 Evaluation of joint dynamic treatment and static mon-
itoring interventions
3.1 Causal estimands
Here we evaluate joint interventions that combine the previously defined dynamic interven-
tion on treatment initiation with a static intervention on monitoring. This evaluation can
be conducted either to determine the combination of a dynamic treatment strategy and A1c
monitoring schedule that achieves the best health outcomes, to improve the generalizability of
findings about the comparative effectiveness of the four dynamic treatment-censoring strate-
gies to settings with specific A1c monitoring schedules, or to determine the frequency of A1c
monitoring that achieve the best outcomes in settings where a specific dynamic treatment-
censoring strategy is followed.
While any static monitoring regimes could be evaluated, for this study we focus on the fol-
lowing four regular monitoring schedules: monitor A1c every quarter (i.e., n¯ = (1, 1, . . . , 1)),
skip one quarter between A1c tests (i.e., n¯ = (0, 1, 0, 1, . . .)), skip two quarters between A1c
tests (i.e., n¯ = (0, 0, 1, 0, 0, 1 . . .)), skip 3 quarters between A1c tests (i.e., n¯ = (0, 0, 0, 1, 0, 0-
, 0, 1, . . .)), where we recall that, by design, all patients have their A1c monitored at study
entry (i.e., N(−1) = 1) and that the first element of each vector n¯ denotes the decision made
at time t = 0 on whether the patient’s A1c will be monitored at time t = 1 (i.e., whether
I0(1) is observed). The collection of these four static monitoring interventions is denoted by
N¯ .
We consider all sixteen possible joint interventions (dx, n¯) of the four previously defined
dynamic treatment-censoring regimes dx with x ∈ X and the four static monitoring regimes
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n¯ ∈ N¯ defined above. For example, one possible joint regime of interest is "Monitor A1c levels
every 3 months, and intensify diabetes treatment the first time A1c drifts above 7.5 %, and
keep the patient on the intensified therapy thereafter." As before, each such intervention also
requires that the patient remains uncensored. The counterfactual outcomes under these 16
interventions are defined by the NPSEM introduced in Section 1.4 and denoted by Ydx,n¯(t+1).
Their distributions define the causal estimands of interest in this section:
ψ(dx1 ,n¯1),(dx2 ,n¯2)(t0 + 1) = P (Ydx1 ,n¯1(t0 + 1) = 1)− P (Ydx2 ,n¯2(t0 + 1) = 1). (6)
3.2 Identifying assumptions
In order to identify the causal parameter defined above, the SRA and positivity assumptions
continue to be required but their expressions are modified as follows to reflect the change in
the interventions of interest.
The SRA can now be expressed as:
Ydx,n¯(t0 + 1) ⊥ (A(t), N(t))|L¯(t), A¯(t− 1), N¯(t− 1), (7)
for t = 0, . . . , t0, x ∈ X , and n¯ ∈ N . In practice, this assumption can be motivated by
ensuring that all backdoor paths from A1(t), A2(t), and N(t) to Y (t0+1) are blocked by prior
measured variables (exposures or covariates) included in the observed data O. For instance,
the SRA (7) will hold if the two gray dashed arrows from U1 and U2 to N(0) are deleted
from the DAG at the bottom of Figure 1. We note that it has been argued that the SRA (7)
might often be less likely to hold than the SRA (2) in EHR-based studies because "data on
the reason for a given visit are often not recorded for data analysis".9 Although we cannot be
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sure that the SRA (7) holds in the EHR-based TI study, the stability in the point estimates
from the secondary analyses with and without adjustment for the monitoring variables N(t)
presented in the prior section provides some support for the stronger assumption (7).
The positivity assumption can now be stated as follows:
P
(
A(t) = dx(t)(V (t))
∣∣∣ L¯(t), Y¯ (t) = 0, A¯(t− 1) = dx(V¯ (t− 1)), N¯(t− 1) = n¯(t− 1)) > 0,
P
(
N(t) = n(t)
∣∣∣ L¯(t), Y¯ (t) = 0, N¯(t− 1) = n¯(t− 1), A¯(t) = dx(V¯ (t))) > 0,
(8)
for t = 0, . . . , t0, x ∈ X , and n¯ ∈ N¯ .
In particular, equation (8) requires that for all time periods and any combination of
past covariates, there is a positive probability for each patient who previously followed the
joint treatment-censoring-monitoring intervention to continue to follow the monitoring inter-
vention of interest. Near-violations of this assumption can occur if certain covariates (e.g.,
change in A1c control) are strong determinants of monitoring decisions (e.g., the American
Diabetes Association recommends that patients who recently changed treatments or whose
A1c recently became out of control be monitored more frequently)
3.3 A hazard-based, bounded, IPW estimator
The bounded IPW estimator (4) is modified in the following way to derive an IPW estimator
denoted by Pn(Ydx,n¯(t + 1) = 1|Ydx,n¯(t) = 0) of the counterfactual hazards under each of
the 16 joint dynamic treatment-censoring and static monitoring interventions described in
this Section. The inverse probability weights hi(t) are now based on the joint conditional
probability of receiving the observed exposure and the observed monitoring interventions.
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More specifically, h(t) is now defined as:
I
(
Y (t) = 0, A¯(t) = dx(V¯ (t)), N¯(t) = n¯(t)
)
∏t
j=0 P
′
n
(
A(j) = dx(j)(V¯ (j)), N(j) = n(j)
∣∣ A¯(j − 1) = dx(V¯ (j − 1)), N¯(j − 1) = n¯(j − 1))∏t
j=0 Pn
(
A(j)
∣∣ L¯(j), A¯(j − 1), N¯(j − 1))Pn(N(j) ∣∣ L¯(j), A¯(j), N¯(j − 1))
(9)
where Pn(N(j)|L¯(j), A¯(j − 1), N¯(j − 1)) denotes an estimate of the conditional probability
of the observed monitoring decision at time j, given the past covariates, exposures and
monitoring decisions (i.e, an estimated propensity score for monitoring when N(j) = 1) and
where
P
′
n
(
A(j) = dx(j)(V¯ (j)), N(j) = n(j) | A¯(j − 1) = dx(V¯ (j − 1)), N¯(j − 1) = n¯(j − 1)
)
is a stabilizing factor denoting the estimated probability of a patient following both the
dynamic treatment-censoring and static monitoring regimen (dx, n¯) at time j given she fol-
lowed both treatment-censoring and monitoring interventions (dx, n¯) through time j − 1.
The IPW estimators of the counterfactual hazards above are then mapped into an esti-
mator ψ(dx1 ,n¯1),(dx2 ,n¯2)n of the causal estimands (6) as follows:
t0∏
t=0
(
1−Pn(Ydx2 ,n¯2(t+1) = 1|Ydx2 ,n¯2(t) = 0)
)
−
t0∏
t=0
(
1−Pn(Ydx1 ,n¯1(t+1) = 1|Ydx1 ,n¯1(t) = 0)
)
and a conservative estimate of its variance is given by a straightforward extension of the
results presented in the Appendix of.20
3.4 Implementation
In order to construct the weights defined in (9), beyond estimating the propensity scores
for the treatment and censoring variables using the logistic regressions described in Section
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2.4, we now also estimate the probability of A1c monitoring at each time point t given the
treatment at time t and the observed past, i.e., P (N(t) = 1|L¯(t), A¯(t), N¯(t− 1)) by fitting a
single logistic regression model with data pooled over all time periods. The model includes
a term for time t, the treatment at time t (A1(t)) and each of the the same covariates (L(t))
and summary measures of their histories through period t used in the propensity score model
for the exposure variable described in Section 2.4, among them the categorical variables indi-
cating the past frequency of A1C monitoring, the categorical variable indicating whether the
latest A1c measurement was monitored at the current period or carried forward from a pre-
vious period, and their interactions with the latest A1c value (I(t)). In addition, we included
terms for the categorical variables that encode a discretized version of the observed A1c I(t)
corresponding with the A1c intervals < 7%; ]7%;7.5%]; ]7.5%;8%]; ]8%;8.5%]; > 8.5%. For
all covariates Z(t) (e.g. LDL, blood pressure) that were not systematically monitored at
each time point t, we also used LOVCF to define the covariate when it was not monitored,
and included the indicators of last value being carried forward in the vector of covariates
L(t) that define the main terms included in the logistic models for the propensity scores.
The estimates of the probabilities P ′n that define the numerators of the IP weights (9) were
derived non-parametrically using proportions of observed events. The estimated stabilized
IP weights were truncated at the value 40.
3.5 Results
Figure 4 shows the numbers of patients following each of 16 joint treatment-censoring-
monitoring interventions for the first 8 periods and can be compared to their analogs without
monitoring interventions in Figure 2 (top left panel). These results confirm that the counts of
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patients following any of the joint interventions are much lower in general than their analogs
without monitoring interventions. As shown in Figure 2, the information to evaluate the dy-
namic treatment-censoring intervention d7.0 is relatively limited compared to the other three
dynamic treatment-censoring interventions. When combining the intervention d7.0 with any
of the four monitoring interventions, Figure 4 (top left panel) indicates that there is very
little information left to evaluate such joint interventions.
Whichever the dynamic intervention, Figure 4 also indicates that the joint interventions
that require monitoring at each period (denoted by n¯0) are followed by significantly fewer
patients than those that require consecutive A1C tests to be separated by 1, 2 or 3 periods
(denoted by n¯1, n¯2, and n¯3, respectively). Whichever the dynamic intervention, Figure 4 also
indicates that the counts of patients who follow any of the joint interventions indexed by the
last three monitoring patterns are very similar at each time point, and as expected, the counts
are in fact identical at time 0 (because all three monitoring patterns require that n(0) = 0)
and remain identical for n¯2 and n¯3 at time 1 because both continue to require n(1) = 0 (unlike
n¯1 for which n1(1) = 1). Starting at time 2, the counts for all joint interventions indexed
by these three monitoring patterns are systematically different but very close in magnitude.
Despite the similarity in available information to evaluate the joint interventions defined by
n¯1, n¯2, and n¯3, we note that the number of patients who follow joint interventions indexed by
the monitoring pattern n¯1 is almost always slightly larger than all other joint interventions
indexed by the other three monitoring patterns. In addition, the counts of patients who
follow each of the 9 joint interventions (dx, n¯j) for x ̸= 7.0 and j ̸= 0 at time 0 is consistently
lower by about 8,000 patients compared to their analogs shown on Figure 2. This drop in
the counts of patients following these 9 joint interventions becomes more drastic at time 1
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and reaches at least 20,000 patients. Beyond the 6th period (a year and a half), none of the
joint regimes are followed by more than a few patients.
We contrast the counterfactual survival curves denoted by the 16 joint treatment censoring-
monitoring interventions, first by comparing the four dynamic treatment-censoring interven-
tions when they are all combined with the same monitoring intervention (Figures 5 and 6),
and second by comparing the four monitoring interventions when they are all combined with
the same dynamic treatment-censoring intervention (Figures 7 and 8). The decrease in avail-
able information described earlier when combining the four dynamic treatment-censoring
strategies with a particular monitoring pattern explains the large increase in the standard er-
rors of the IPW risk difference estimators (i.e., the width of confidence intervals) displayed in
Figure 6 compared to those displayed at the bottom of Figure 3. Despite this large reduction
in precision, all plots except for the bottom right one on Figure 5 show a similar separation
and ordering of the survival curves compared to those obtained without monitoring interven-
tions and displayed in the bottom right plot on Figure 2. In other words, these results also
suggest that the risk of onset or progression of albumbinuria decreases with the decrease of
the A1c threshold at which an intensified treatment is initiated. We note that the increase
in estimation variability also likely explains why the survival curves in Figure 5 are erratic
compared to those in 2. The strongest statistical evidence to support a protective effect of
treatment intensification at a lower A1c threshold is obtained for the monitoring intervention
n¯1 as shown on the top right plot of Figure 6. When contrasting joint interventions defined by
different monitoring interventions but the same dynamic treatment-censoring intervention on
Figure 7, results suggest a beneficial effect of more frequent monitoring on the risk of onset or
progression of albuminuria. Despite the relatively consistent trend in the point estimates of
33
the risk difference on Figure 8, the wide confidence intervals do not provide strong statistical
evidence of a protective effect of more frequent A1c monitoring.
Table 3 displays the distribution of the stabilized and untruncated IP weights for person-
time-regime outcomes during the first 8 quarters of follow-up with nonzero weight values.
We note that the distribution of the IP weights is shifted right compared to that for regimes
without monitoring interventions displayed in Table 2 and, in particular, the number of
weights greater than or equal to 40 and 150 is now 110 and 13, respectively, out of 597,111
observations contributing to the analysis of joint interventions compared to 13 and 0 out of
651,250 in the analysis without monitoring intervention. This shift and increase in the number
of large weights confirm theoretical concerns over increased near-violations of the positivity
assumption (8) when evaluating dynamic treatment-censoring interventions combined with
monitoring interventions. Table 4 indicates that almost all weights greater than 40 and 150
are assigned to observations contributing to the evaluation of joint interventions that require
continuous A1c monitoring. Based on the difference between the distributions of the weights
in Tables 3 and 4 and the histograms in Figure 4, we conjecture that the observed increase in
near-violations of the positivity assumption is likely resulting from the large reduction in the
number of patients following each joint intervention (i.e., it could be avoided with increased
sample sizes) but note that it may also be indicative of the existence of covariate events that
are strong determinants of monitoring decisions (i.e., structural violations that would persist
with increased sample sizes).
34
d8.0 d8.5
d7.0 d7.5
0 2 4 6 0 2 4 6
0
10000
20000
30000
40000
50000
0
10000
20000
30000
40000
50000
time
co
u
n
t
Monitoring regime
n0
n1
n2
n3
Figure 4: Counts of patients following each of the 16 joint treatment-censoring and
monitoring interventions over time. Counts are organized by dynamic treatment-censoring
interventions. The static monitoring interventions require that two consecutive A1c tests
always be separated by 0, 1, 2, and 3 periods and are denoted by n¯0, n¯1, n¯2, and n¯3,
respectively.
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Figure 5: IPW estimates of the counterfactual survival curves under the 16 joint dynamic
treatment-censoring-monitoring interventions. Each plot contrasts the four counterfactual
survival curves defined by four distinct dynamic treatment-censoring interventions and a
single static monitoring intervention. Clockwise starting with the top left plot, the static
monitoring intervention requires that two consecutive A1c tests always be separated by 0,
1, 3, and 2 periods and is denoted by n¯0, n¯1, n¯3, and n¯2, respectively, in the caption of each
plot.
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Figure 6: IPW estimates of counterfactual risk differences between dynamic
treatment-censoring regimes combined with a given static monitoring intervention. The
shaded areas represent the 95% confidence intervals. Clockwise, starting with the top left
plot, the static monitoring intervention requires that two consecutive A1c tests always be
separated by 0, 1, 3, and 2 periods and is denoted by n¯0, n¯1, n¯3, and n¯2, respectively, in the
caption of each plot.
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Figure 7: IPW estimates of the counterfactual survival curves under the 16 joint dynamic
treatment-censoring and monitoring interventions. Each plot contrasts the four
counterfactual survival curves defined by four distinct static monitoring interventions and a
single dynamic treatment-censoring intervention. The static monitoring regimes contrasted
on each plot require that two consecutive A1c tests always be separated by 0, 1, 2, and 3
periods and are denoted by n¯0, n¯1, n¯2, and n¯3, respectively.
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Figure 8: IPW estimates of counterfactual risk differences between static monitoring
regimes combined with a given dynamic treatment-censoring intervention. The shaded
areas represent the 95% confidence intervals. The four static monitoring interventions
contrasted in each plot require that two consecutive A1c tests always be separated by 0, 1,
2, and 3 periods and are denoted by n¯0, n¯1, n¯2, and n¯3, respectively.
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Table 3: Distribution of stabilized inverse probability weights for evaluating causal
estimand (6). Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 24829 4.16 24829 4.16
[0.5, 1[ 364741 61.08 389570 65.24
[1, 10[ 204120 34.18 593690 99.43
[10, 20[ 2821 0.47 596511 99.90
[20, 30[ 392 0.07 596903 99.97
[30, 40[ 98 0.02 597001 99.98
[40, 50[ 34 0.01 597035 99.99
[50, 100[ 56 0.01 597091 100.00
[100, 150[ 7 0.00 597098 100.00
≥ 150 13 0.00 597111 100.00
Table 4: Distribution of the subset of stabilized inverse probability weights for evaluating
causal estimand (6) when n¯1 and n¯2 do not enforce continuous A1c monitoring.
Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 19804 3.58 19804 3.58
[0.5, 1[ 334828 60.51 354632 64.09
[1, 10[ 195915 35.40 550547 99.49
[10, 20[ 2461 0.44 553008 99.93
[20, 30[ 292 0.05 553300 99.99
[30, 40[ 55 0.01 553355 100.00
[40, 50[ 11 0.00 553366 100.00
[50, 100[ 3 0.00 553369 100.00
[100, 150[ 0 0.00 553369 100.00
≥ 150 0 0.00 553369 100.00
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4 Evaluation of joint dynamic treatment-censoring and
static monitoring interventions under the no direct ef-
fect assumption
4.1 Causal estimands
Under the NDE assumption detailed below, the causal parameters (6) in the prior Section
were shown by15 to equal the following causal estimands that are of interest here:
ψ(d
∗
x1
,g∗1),(d
∗
x2
,g∗2)(t0 + 1) = P (Yd∗x1 ,g
∗
1
(t0 + 1) = 1)− P (Yd∗x2 ,g∗2 (t0 + 1) = 1), (10)
where each d∗xj with xj ∈ X is a modified version of the dynamic treatment-censoring inter-
vention dxj and where each g∗j is a static monitoring intervention on a subset of the moni-
toring process. Both interventions d∗xj and g
∗
j are defined as follows based on the same static
monitoring intervention n¯j ∈ N . Instead of requiring a patient to follow the pre-specified
monitoring intervention n¯j at every time point, the static monitoring intervention g∗j requires
patients to be monitored at least at the pre-specified set of time points t when nj(t) = 1, but
does not constrain monitoring decisions at other time points, i.e., it allows for the monitor-
ing process to take its natural course for the remaining time points t when nj(t) = 0. The
modified dynamic treatment-censoring intervention d∗xj differs from the previously defined
decision rule dxj in that it only uses the past A1c measurements which are observed both
under the monitoring regime n¯j, and under the actual observed monitoring process N¯(j),
i.e., d∗xj(t)(V (t)) = dxj(t)(V
∗(t)) where we recall that V (t) = (A(t− 1), N(t− 1), Y (t), I(t))
and where we define V ∗(t) = (A(t − 1), nj(t − 1)N(t − 1), Y (t), nj(t − 1)I(t)). Thus, the
modified dynamic treatment-censoring interventions d∗xj corresponds to the original dynamic
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treatment-censoring intervention dxj except that it requires that any additional A1c mea-
surements collected beyond the A1c measurements required under intervention n¯j be ignored
when applying the decision rule dxj .
4.2 Identifying assumptions
While the causal estimands (10) can be of interest in their own rights, we focus our discussions
on their use as an indirect approach to the evaluation of the causal estimands (6) introduced
in the prior Section. We note that the identifiability of the causal estimands (10) relies only
on the SRA and positivity assumption detailed below. However, if the causal estimands
(10) are evaluated as an indirect mean to estimating the causal estimands (6), an additional
identifiability assumption referred to as the No Direct Effect assumption is required. This
assumption is formalized by the equality of counterfactual covariates under two sets of static
interventions introduced in:9
L0a¯,n¯(t) = L
0
a¯(t), (11)
where L0(t) = (Y (t), Z(t), I0(t)).In the NPSEM framework, it was shown by (15) that this
assumption is implied by an exclusion restriction assumption that requires that all directed
paths from nodes N(t) to subsequent covariates Y (j), Z(j), and I0(j) be intercepted by
treatment or censoring nodes A(t) for j > t. In the DAG at the bottom of Figure 1,
this assumption is encoded by the exclusion of the three solid gray arrows from N(0) to
Y (1), I0(1), and Y (2). Under the NDE assumption, the counterfactual outcomes defined
by the joint treatment, censoring, and monitoring intervention (d∗xj , g
∗
j ) was shown by15 to
equal the counterfactual outcomes of the joint intervention (dxj , n¯j). The causal estimands
(6) and (10) then become equivalent, i.e., ψ(dx1 ,n¯1),(dx2 ,n¯2)(t0 + 1) = ψ(d
∗
x1
,g∗1),(d
∗
x2
,g∗2)(t0 + 1).
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Consequently, the IPW estimator of the causal estimands (10) that we describe in the next
section can be used as an indirect estimator of the causal estimands (6) when the NDE
assumption holds. The potential advantage of this indirect IPW estimator over the direct
IPW estimator described in Section 3.3 can be brought to light by comparing the SRA
and positivity assumption required to identify estimands (10) with their analogs required to
identify estimands (6).
The SRA required for identification of the causal estimand (10) can be expressed as:
Yd∗xj ,g
∗
j
(t0 + 1) ⊥ (A(t), N(t))|L¯(t), A¯(t− 1), N¯(t− 1) for all t such that nj(t) = 1
Yd∗xj ,g
∗
j
(t0 + 1) ⊥ A(t)|L¯(t), A¯(t− 1), N¯(t− 1) for all t such that nj(t) = 0,
(12)
with t = 0, . . . , t0. We note that this assumption is weaker than SRA (7) in the sense that it
holds even when some backdoor paths from N(t) to Y (t0+1) are not blocked by variables in
O collected before N(t) and as long as such open backdoor paths only occur at time points
t when nj(t) = 0. However, this change in the SRA requirement is not likely to be of much
practical value because we do not expect it to result in the selection of different covariate sets
for confounding and selection bias adjustment in practice. In other words, we expect that
most arguments in favor of or against the upholding of SRA (7) will typically also apply to
the upholding of the SRA (12) and vice versa.
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The positivity assumption for identification of the causal estimand (10) can be stated as:
P
(
A(t) = d∗xj(t)(V (t))
∣∣∣ L¯(t), Y¯ (t) = 0, A¯(t− 1) = d∗xj(V¯ (t− 1)),
N¯(t− 1) = g∗j (N¯(t− 1))
)
> 0
for t = 0, . . . , t0 and,
P
(
N(t) = 1
∣∣∣ L¯(t), Y¯ (t) = 0, N¯(t− 1) = g∗j (N¯(t− 1)), A¯(t) = d∗xj(V¯ (t))) > 0
for t = 0, . . . , t0 such that nj(t) = 1,
(13)
where g∗j (N¯(t)) =
(
g∗j (0)(N(0)), . . . , g
∗
j (t)(N(t)
)
is defined by the mappings g∗j (k) : N(k) 7→
N(k)1−nj(k) for k = 0, . . . , K as the sequence of monitoring decisions through time t that is
consistent with following intervention g∗j and compatible with the subset of observed moni-
toring decisions that are not constrained by intervention g∗j .
We note that the positivity assumption (13) requires that the A1c of a patient who
previously followed the intervention (d∗xj , g
∗
j ) be possibly monitored at only the time points
t ≤ t0 when nj(t) = 1, whichever the patient’s covariate and monitoring history. This
is in contrast to the positivity assumption (8) that requires that a patient who previously
followed the intervention (dxj , n¯j) have its A1c monitored at all time points t ≤ t0 according
to the static intervention nj(t), whichever the patient’s covariate history. It can thus be
expected that the positivity assumption (13) will often be more likely to hold in practice
than its analog (8). For example, if n¯j = (0, 0, 1, 0, 0, 1, ...), the positivity assumption (13)
only requires that each patient can possibly be monitored every third quarter and does not
place any constraint on the monitoring decisions between these yearly monitoring events,
while the positivity assumption (8) requires that each patient can possibly experience the
exact sequence of monitoring decisions n¯j throughout follow-up.
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The practical consequences of this weakening of the positivity assumption are expected
improvements in IPW estimation performance, both in terms of finite sample bias and preci-
sion because of the likely more stable IP weights (e.g., fewer extreme weight values or more
compact weight distribution), and the increased number of person-time observations with
nonzero weight values, i.e., the increase in the number of patients whose observed exposure
and monitoring history is consistent with following the joint treatment-censoring-monitoring
intervention at each time point. However, we note that this potential for improved practical
performance in the estimation of the causal estimand (10) over that of (6) might be offset by
the fact that the positivity assumption for the exposure process in (13) can conceivably be
more likely violated in practice than that in (8).
Indeed, the specification of the dynamic interventions dxj that are evaluated in practice
often integrates considerations about the occurrence of intermediate events (e.g., contraindi-
cations) that should preclude certain treatment decisions to occur.42 In fact, it is such a
consideration that originally motivated16 the evaluation of the four dynamic interventions
studied in this paper over static alternatives in the TI study (e.g., start an intensified treat-
ment 1 years versus 2 years after study entry). Specifically. the expectation that most
patients would not remain unexposed to an intensified therapy if their A1c drifted above a
high threshold (>8.5%) raised concerns over the violation of the positivity assumption that
would be required for identifying the effects of static interventions. This same consideration
raises concerns here over a possible violation of the positivity assumption requirements for
the exposure process in (13) because the treatment decision at time t according to rule d∗xj
would require, for example, that a patient remain unexposed to an intensified therapy even
if an A1c measurement collected at time t reached a very high level and that simply because
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this measurement I(t) happened to be collected at a time point t when n¯j(t) = 0. Later in
this section, we examine the trade-off between improved IP weight stability resulting from
interventions on fewer monitoring nodes with g∗j and worsened IP weight stability resulting
from poorer adherence to decision rule d∗xj by comparing the practical performance of the
IPW estimator introduced next to that of the IPW estimator from Section 3.3 for estimating
the causal estimand (6) under the NDE assumption.
4.3 A hazard-based, bounded, IPW estimator
The bounded IPTW estimator introduced in Section 3.3 for evaluating the counterfactual
hazards under the 16 joint dynamic treatment-censoring and static monitoring monitoring
interventions (dx, n¯) is modified in the following way to derive an IPW estimator denoted
by Pn(Yd∗xj ,g∗j (t + 1) = 1|Yd∗xj ,g∗j (t) = 0) of the counterfactual hazards under each of the 16
interventions (d∗xj , g
∗
j ). The inverse probability weights hi(t) are now defined by the modified
function h(t):
I
(
Y (t) = 0, A¯(t) = dx(V¯ (t)), N¯(t) = g
∗
j (N¯(t))
)
∏t
k=0 P
′
n
(
A(k) = d∗xj (k)(V¯ (k)), N(k) = g
∗
j (k)(N(k))
∣∣ A¯(k − 1) = d∗xj (V¯ (k − 1)), N¯(k − 1) = g∗j (N¯(k − 1)))∏t
k=0 Pn
(
A(k)
∣∣ L¯(k), A¯(k − 1), N¯(k − 1))∏k=0,...,t:nj(k)=1 Pn(N(k) ∣∣ L¯(k), A¯(k), N¯(k − 1)) ,
(14)
where
P
′
n
(
A(k) = d∗xj (k)(V¯ (k)), N(k) = g
∗
j (k)(N(k))
∣∣ A¯(k − 1) = d∗xj (V¯ (k − 1)), N¯(k − 1) = g∗j (N¯(k − 1)))
is a stabilizing factor denoting the estimated probability of a patient following both the
dynamic treatment-censoring and static monitoring regimen (d∗xj , g
∗
j ) at time k given she
followed both the treatment-censoring and monitoring interventions (dxj , g∗j ) through time
k − 1. We note that, unlike the weight function (9), the function h(t) does not involve the
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terms Pn(N(k)|L¯(k), A¯(k), N¯(k − 1)) for time points k when nj(k) = 0 in the denominator and the
resulting weights hi(t) can thus be expected to have a more compact distribution and be less
prone to take on large values.
The IPW estimators of the counterfactual hazards above are then mapped into an esti-
mator ψ
(d∗x1 ,g
∗
1),(d
∗
x2
,g∗2)
n of the causal estimands (10) as follows:
t0∏
t=0
(
1−Pn(Yd∗x2 ,g∗2 (t+1) = 1|Yd∗x2 ,g∗2 (t) = 0)
)
−
t0∏
t=0
(
1−Pn(Yd∗x1 ,g∗1 (t+1) = 1|Yd∗x1 ,g∗1 (t) = 0)
)
and a conservative estimate of its variance is given by a straightforward extension of the
results presented in the Appendix of.20
We recall that this IPW estimator and its variance estimator are consistent for estimating
the causal estimand (10) if the SRA (12) and positivity assumption (13) hold and if the
denominators of the IP weight h(t) are consistent estimators of the exposure and monitoring
assignment mechanisms, i.e., the true unknown conditional probabilities P (A(k)|L¯(k), A¯(k−
1), N¯(k − 1)) and P (N(k)|L¯(k), A¯(k), N¯(k − 1)). If the NDE assumption also holds, then
this IPW estimator and its variance estimators are also consistent for estimating the causal
estimand (6).
4.3.1 Implementation
The exact same estimates (i.e., same logistic model fits) of the propensity scores for the
exposure and monitoring variables that are used to implement the denominator of the IP
weights (9) are also used to implement the denominator of the IP weights (14). Similarly, the
estimates of the probabilities P ′n that define the numerators of the IP weights were derived
non-parametrically using proportions of observed events. Thus, the only difference between
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the IPW estimator implementation here and in Section 3.3 is how estimates of the numerators
and denominators of the weights are assembled to define the weights hi(t) assigned to each
outcome over time (i.e., the difference between formulas (9) and (14)). In particular, the set
of outcomes that contribute to each IPW estimate (4) is different because it is defined by the
set of patients i for a given t, x ∈ X and n¯ ∈ N such that hi(t) ̸= 0. All stabilized weights
were also truncated at 40 as in prior analyses.
4.4 Results
Figure 9 shows the numbers of patients following each of 16 joint treatment-censoring-
monitoring interventions (d∗x, g∗) for the first 8 periods and can be compared to their analogs
(dx, n¯) in Figure 4. These results confirm that the counts of patients following any of the
joint interventions (d∗x, g∗) is larger than their analogs (dx, n¯), except, as expected, when
these two interventions are defined based on n¯0. Indeed, the set of patients following each
of the two interventions is then identical at each time point because g∗0 = n¯0 which, in turn,
implies d∗x = dx (because V ∗(t) = V (t) when g∗0 = n¯0). At time 0, Figure 9 indicates that,
1) the number of patients following any given intervention (d∗x, g∗) defined by n¯j with j ̸= 0
is identical whichever the definition of g∗ (i.e., the value of j) and, 2) for each x ∈ X , this
number is equal to the number of patients following the intervention dx as shown by com-
parison with the top left panel of Figure 2. These results are expected because V ∗(0) = V (0)
for all n¯ and because the interventions g∗ defined by n¯j for j = 1, 2, 3 do not enforce an
intervention on monitoring at time 0 and, as a result, the intervention dx is equivalent to the
three interventions (d∗x, g∗) at time 0. Figure 9 also indicates that, at time 1, the number
of patients following any given intervention (d∗x, g∗) defined by n¯j with j = 2, 3 is identical
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whichever the definition of g∗ (i.e., the value of j) and, for each value of x ∈ X , this number
is very close but slightly different from the number of patients following the intervention dx
as shown by comparison with the top left panel of Figure 2. This result reflects the fact
that both the interventions g∗ defined by n¯j with j = 1, 2 do not enforce an intervention
on monitoring at t = 0, 1 and thus the difference between intervention (d∗x, g∗) and dx at
time 1 comes down to the difference between applying the same decision rule dx when any
A1c collected at time 1 is ignored versus used to determine treatment at time 1. The same
results and explanation apply to time 2 with j = 3 as shown by examining Figure 9 and
comparing it to the top left panel of Figure 2. Figure 9 indicates that, starting at time 2 and
for each x ∈ X , the number of patients following each joint intervention (d∗x, g∗) defined by
n¯j almost always increases with the decrease in the frequency of A1c monitoring (i.e., with
the increase in j). This result differs from that observed for interventions (dx, n¯) in Figure
4 and demonstrates that the expected increase in the number of patients who follow the
monitoring intervention g∗ defined by n¯j as j increases (because it enforces interventions on
a smaller subset of monitoring events) is not offset in this study by a decrease in the number
of patients who follow the intervention d∗x over dx.
We contrast the counterfactual survival curves denoted by the 16 joint treatment-censoring-
monitoring interventions (d∗x, g∗), first by comparing the four dynamic treatment-censoring
interventions when they are all combined with the same monitoring intervention (Figures
10 and 11), and second by comparing the four monitoring interventions when they are all
combined with the same dynamic treatment-censoring intervention (Figures 12 and 13). We
note that the equivalence between intervention (dx, n¯0) and (d∗x, g∗0) for each x ∈ X described
above explains that the plots on the top left panel of Figures 5 (resp. 6) and 10 (resp. 11)
49
are identical. This equivalence also explains why, on all panels of Figures 7 and 12, the red
survival curves corresponding with the monitoring intervention n¯0 and g∗0, respectively, are
identical. The increase in the number of patients following the joint interventions (d∗x, g∗)
compared to (dx, n¯) described earlier explains the large decrease in the standard errors of the
IPW risk difference estimators (i.e., the width of confidence intervals) displayed in Figures
11 and 13 compared to those displayed in Figures 6 and 8, respectively. The large increase in
available information when g∗ is defined based on n¯j ̸= n¯0 leads to survival curves estimates
on Figure 11 that are much smoother than that displayed on Figure 6. There is now a clear
separation and consistent ordering of the survival curve estimates over time for all three inter-
ventions g∗ defined by n¯j with j ̸= 0 and results are now very similar to the estimates obtained
without monitoring intervention (bottom panel of Figure 2). Whichever the definition of the
intervention d∗x, results from the joint treatment-censoring-monitoring interventions (d∗x, g∗)
indicate that the risk of onset or progression of albumbinuria decreases with the decrease of
the A1c threshold at which an intensified treatment is initiated. Unlike evidence from Figure
6, the precision in the risk difference estimates displayed in Figure 11 now provides strong
statistical evidence of a protective effect of treatment intensification at a lower A1c threshold
when g∗ is defined based on n¯j with j = 1, 2, 3. When contrasting joint interventions defined
by different monitoring interventions but the same dynamic treatment-censoring intervention
on Figure 12, results suggest a decreased risk of onset or progression of albuminuria for any
given treatment-censoring intervention d∗x with x ∈ X when the monitoring intervention g∗
is defined by n¯j with j increasing. This result can be approximated by stating that more
frequent A1c monitoring results in improved outcome. We note that the estimates of this
suggested beneficial effect tend however to be smaller than those displayed on Figure 7 for
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intervention (dX , n¯). Despite the tighter confidence intervals for the risk difference on Figure
13 compared to those on Figure 8, the general decrease in the point estimates of the risk
differences lead to similarly weak statistical evidence of a protective effect of more frequent
A1c monitoring.
Table 5 displays the distribution of the stabilized and untruncated IP weights for person-
time-regime outcomes during the first 8 quarters of follow-up with nonzero weight values. We
note that the distribution of the IP weights is shifted left compared to that for interventions
(dx, n¯) displayed in Table 3 but that it remains slightly shifted right compared to that for
regimes without monitoring interventions displayed in Table 2. A cursory comparison of
the proportions of large weights between Tables 5 and 3 suggests no worsening in near-
violations of the positivity assumption. Indeed, the number of weights greater than or equal
to 40 and 150 less than doubles even though the number of regime-person-time observations
more than doubles when evaluating joint interventions (d∗x, g∗) instead of (dx, n¯). When
excluding observations associated with interventions (d∗x, g∗) defined by n¯j with j = 0 (i.e.,
interventions that are then equivalent to (dx, n¯0)), Table 6 shows a relatively large increase
in the proportions of weights greater than or equal to 40 and 150 compared to Table 4. This
increase in the number of large weights despite the increase of the number of patients following
the interventions (d∗x, g∗) over (dx, n¯) confirms the theoretical concerns that we detailed earlier
over increased near-violations of the positivity assumption requirements for the exposure
process in (13) compared to (8). These secondary data analyses demonstrate that efficiency
gains that result from greater numbers of patients following interventions (d∗x, g∗) compared
to interventions (dx, n¯) could be offset by increased finite-sample bias resulting from near-
violations of the positivity assumption.
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Figure 9: Counts of patients following each of the 16 joint treatment-censoring and
monitoring interventions (d∗x, g∗j ) over time. Counts are organized by dynamic
treatment-censoring interventions. The static monitoring interventions g∗j on the subset of
the monitoring process is defined by the monitoring regime n¯j that requires that two
consecutive A1c tests always be separated by j period(s).
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Figure 10: IPW estimates of the counterfactual survival curves under the 16 joint dynamic
treatment-censoring and monitoring interventions (d∗x, g∗j ). Each plot contrasts the four
counterfactual survival curves defined by four distinct dynamic treatment-censoring
interventions and a single static monitoring intervention. The static monitoring
intervention g∗j on the subset of the monitoring process is defined by the monitoring regime
n¯j that requires that two consecutive A1c tests always be separated by j period(s).
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Figure 11: IPW estimates of counterfactual risk differences between dynamic
treatment-censoring regimes d∗x combined with a given static monitoring intervention g∗j .
The shaded areas represent the 95% confidence intervals. The static monitoring
intervention g∗j on the subset of the monitoring process is defined by the monitoring regime
n¯j that requires that two consecutive A1c tests always be separated by j period(s).
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Figure 12: IPW estimates of the counterfactual survival curves under the 16 joint dynamic
treatment-censoring and monitoring interventions (d∗x, g∗j ). Each plot contrasts the four
counterfactual survival curves defined by four distinct static monitoring interventions and a
single dynamic treatment-censoring intervention. The static monitoring intervention g∗j on
the subset of the monitoring process is defined by the monitoring regime n¯j that requires
that two consecutive A1c tests always be separated by j period(s).
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Figure 13: IPW estimates of counterfactual risk differences between static monitoring
regimes g∗j combined with a given dynamic treatment-censoring intervention d∗x. The
shaded areas represent the 95% confidence intervals. The static monitoring intervention g∗j
on the subset of the monitoring process is defined by the monitoring regime n¯j that requires
that two consecutive A1c tests always be separated by j period(s).
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Table 5: Distribution of stabilized inverse probability weights for evaluating causal
estimand (10). Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 105209 8.49 105209 8.49
[0.5, 1[ 952594 76.90 1057803 85.40
[1, 10[ 174362 14.08 1232165 99.47
[10, 20[ 5400 0.44 1237565 99.91
[20, 30[ 752 0.06 1238317 99.97
[30, 40[ 192 0.02 1238509 99.99
[40, 50[ 59 0.00 1238568 99.99
[50, 100[ 93 0.01 1238661 100.00
[100, 150[ 13 0.00 1238674 100.00
≥ 150 20 0.00 1238694 100.00
Table 6: Distribution of the subset of stabilized inverse probability weights for evaluating
causal estimand (10) when n¯1 and n¯2 do not enforce continuous A1c monitoring.
Rule-person-time observations with a weight value of 0 are excluded.
IPW Frequency % Cumulative Frequency Cumulative %
<0 0 0.00 0 0.00
[0, 0.5[ 100184 8.38 100184 8.38
[0.5, 1[ 922681 77.21 1022865 85.60
[1, 10[ 166157 13.90 1189022 99.50
[10, 20[ 5040 0.42 1194062 99.93
[20, 30[ 652 0.05 1194714 99.98
[30, 40[ 149 0.01 1194863 99.99
[40, 50[ 36 0.00 1194899 100.00
[50, 100[ 40 0.00 1194939 100.00
[100, 150[ 6 0.00 1194945 100.00
≥ 150 7 0.00 1194952 100.00
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5 Discussion
With this case study of the evaluation of adaptive treatment strategies with EHR data, we
aimed to provide detailed practical guidance on how to 1) approach the challenges posed by
the non-systematic monitoring of time-varying covariates for confounding adjustment and,
2) exploit such monitoring variability to evaluate its health impact or to improve the gener-
alizibility of CER findings. While the approaches developed were illustrated with EHR data,
they are applicable to any observational study with non-systematic covariate monitoring.
First, using DAG reasoning, we demonstrated that covariate information that was not
systematically collected during follow-up does not necessarily amount to partially missing
data, i.e., data that are needed to adequately account for confounding bias and that, if
ignored, would lead to a violation of the SRA. Instead, we argued that, under an assumption
that is often reasonable in practice, the effects of treatment interventions (dynamic or static)
can be identified simply by including an indicator of monitoring events for the partially
observed covariate in the adjustment set. For instance, a laboratory measurement that
was not ordered by a clinician and that was thus unknown to her cannot influence her
treatment decision (e.g., prescribe a new drug). Consequently, imputation of laboratory
measurements that were not ordered is unnecessary and adjustment for the time-varying
indicator of laboratory monitoring is sufficient for proper confounding adjustment. Our
analytic example demonstrated that the use of indicators for covariate monitoring events to
estimate IP weights does not impede proper confounding adjustment and that it can even lead
to more precise IPW effect estimates. The rationale above questions the relevance of common
practice that treats partially unobserved covariate information as missing and attempts to
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impute it. We argued that even if the imputation of this information is successful, this
common approach may not address confounding by the intensity of monitoring except if it
also involves adjustment for indicators of monitoring events. Thus, we propose that this
imputation approach be instead reserved for covariate measurements that were known to the
decision maker when choosing treatment but that were not captured in the data assembled
for research purposes. With this perspective, the common practice of defining time-varying
covariates by LOVCF should not be construed as an approach for missing data imputation
but merely a pragmatic approach to define time-varying covariates that capture the last
information known to the decision maker when choosing a treatment. When used for this
purpose, LOVCF should thus not be subject to the (valid) criticisms that this approach has
been the target of in the context of missing data imputation such as for the imputation of
missing outcomes due to, for instance, interval censoring (43, MD-2 PCORI standard). We
hope that our results will discourage blanket recommendations against the use of LOVCF
in CER and promote more nuanced guidelines that acknowledge its utility for defining time-
varying covariates used for confounding adjustment in CER with longitudinal observational
data. More importantly, we hope that these results will also encourage routine adjustment for
indicators of monitoring events in IPW analyses or their analogs based on alternate estimators
(e.g., G-computation, augmented-IPW, or targeted minimum loss based estimators).
Second, because the monitoring of the time-varying covariate(s) that are used to adapt
treatment decisions plays a central role in the evaluation of dynamic regimes, we described
and compared the implementation of two IPW estimators for evaluating the joint effects of
dynamic treatment-censoring and static monitoring interventions. To our knowledge, this
report provides the first detailed account of the practical trade-offs between these two IPW
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estimation approaches. Motivations for their applications include the joint optimization
of treatment and monitoring decisions, improved generalizability of study findings, or the
evaluation of the health impact of various monitoring strategies when combined with a given
dynamic treatment intervention. We note that the performance of these estimators hinges
on a stronger SRA whose upholding has been questioned when determinants of monitoring
events are not routinely collected on all subjects such as in EHR-based studies. With our
example, we illustrated the expected poor performance of standard IPW estimation of these
joint effects due to a large decrease in data support to evaluate them which, in turn, can also
increase concerns over finite-sample bias from near-violations of the positivity assumption for
the monitoring process. To alleviate the expected practical limitation of the standard IPW
estimator, we demonstrated how an alternate approach that hinges on an NDE assumption
can result in much improved estimation efficiency due to increased data support but at
the cost of a potential increase in finite-sample bias due to structural near-violations of
the positivity assumption for the treatment process. Evidence from the implementation of
these two IPW estimators in the TI study suggests a beneficial effect of more frequent A1c
monitoring when combined with a dynamic intervention that requires that an intensified
treatment be initiated when A1c reaches or drifts above a threshold >7%.
Results from the evaluation of the joint effects of the four static monitoring interventions
and the dynamic treatment-censoring intervention d7.0 suggest a possible violation of the
NDE assumption in the TI study. Indeed, the dynamic rule d7.0 is equivalent to the static
treatment intervention a¯ = (1, . . . , 1) because, by study design, all patients enter the cohort
with a baseline A1c measurement ≥ 7%. Under the NDE assumption (11), we would thus
expect little to no differentiation between the survival curves in the top left panel of Figure
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7. Instead, these curves indicate a consistent increase in the estimated risk of failure with the
decrease in the frequency of A1c monitoring although these apparent differences generally
do not reach statistical significance as shown on the top left panel of Figure 8. We note that
these estimates could also result from unmeasured confounding of the effect of A1c monitoring
on the outcome, i.e., the NDE assumption could actually hold but biased survival estimates
make it appear as violated. Even if the NDE assumption were violated, we emphasize that
inferences from the alternate NDE-based IPW analyses in this paper can remain causally
interpretable although results become more difficult to convey and use to inform care.
As noted in (9, p. 4703), we might expect a violation of the NDE assumption in intention-
to-treat (ITT) analyses where the dynamic treatment interventions stop after initiation of an
intensified therapy but the monitoring interventions continue past treatment intensification.
For instance in the TI study, the NDE assumption would be violated in such an analysis if
A1c monitoring motivates patient adherence, i.e., the refill of prescriptions for the intensified
therapy later after its initiation. Our analyses were based on the per-protocol principle, i.e.,
the dynamic treatment intervention continues after initiation of an intensified treatment by
requiring that patients remain on the intensified therapy thereafter. We note that an alternate
approach to mitigate concerns over NDE violations in ITT analyses could consist in replacing
the current static monitoring interventions that continue through outcome collection with
equivalent interventions that stop monitoring requirements after the intensified treatment is
initiated. Such an approach would however require extending the identifiability results in
(15).
Finally, we note that an alternate analytic strategy that would not rely on the NDE as-
sumption to address the practical limitations of standard IPW estimators of joint treatment-
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monitoring effects could consist in evaluating stochastic monitoring interventions instead of
static ones. These alternate interventions can lead to the definition of joint effects that are
particularly relevant for patient-centered outcomes research because they can better represent
real-world adherence to rigid monitoring schedules such as the ones studied in this report.
The weakening of the positivity assumption required to identify these effects is expected44
to improve the practical performance of their standard IPW estimators compared to that of
the standard IPW estimators of effects defined by static monitoring interventions.
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